EP2271299B1 - Dispositif pour la conservation, la preparation extemporanee et l'administration de principe actif - Google Patents

Dispositif pour la conservation, la preparation extemporanee et l'administration de principe actif Download PDF

Info

Publication number
EP2271299B1
EP2271299B1 EP09745963A EP09745963A EP2271299B1 EP 2271299 B1 EP2271299 B1 EP 2271299B1 EP 09745963 A EP09745963 A EP 09745963A EP 09745963 A EP09745963 A EP 09745963A EP 2271299 B1 EP2271299 B1 EP 2271299B1
Authority
EP
European Patent Office
Prior art keywords
active principle
head
conserving
administration
extemporaneously
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP09745963A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2271299A1 (fr
Inventor
Philippe Perovitch
Tatiana Galperine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2271299A1 publication Critical patent/EP2271299A1/fr
Application granted granted Critical
Publication of EP2271299B1 publication Critical patent/EP2271299B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2093—Containers having several compartments for products to be mixed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/24—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes
    • B65D51/28—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials
    • B65D51/2807—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container
    • B65D51/2814—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it
    • B65D51/2828—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it said element being a film or a foil
    • B65D51/2835—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it said element being a film or a foil ruptured by a sharp element, e.g. a cutter or a piercer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A61J1/065—Rigid ampoules, e.g. glass ampoules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/202—Separating means
    • A61J1/2027—Separating means having frangible parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2079—Filtering means
    • A61J1/2086—Filtering means for fluid filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2096—Combination of a vial and a syringe for transferring or mixing their contents

Definitions

  • the present invention relates to a device for the preservation and extemporaneous preparation of active ingredients, in particular low dosages, to be administered by injection, local or systemic.
  • the invention also relates to the use of this device for the extemporaneous preparation of active principles for their administration, in particular for the intracameral administration of antibiotics for the prevention of post-phacocystectomy infections, or the injection of ophthalmic treatments in intraveneal.
  • Phacocystectomy is an intervention commonly performed by hospital departments and Ophthalmic Practitioners, which aims to extract and replace with a synthetic prosthesis, an opacified lens subject to cataracts.
  • This procedure consists most often of incising under local anesthesia, the cornea and then the capsule of the lens in the anterior chamber of the eye, and to extract the nucleus of the crystalline lens after its fragmentation by ultrasound.
  • a flexible foldable implant is then introduced into the capsule where it unfolds to be centered by the operator.
  • phacocystectomy leads to a high number of postoperative infections responsible for blindness.
  • a antibiotic such as cefuroxime.
  • Health authorities recommend administering this antibiotic at a dose of 1 mg per 0.1 ml of aqueous solvent.
  • antibiotics suitable for the prevention of post-phacocystectomy infections especially Cefuroxime, are only available at doses between 250 mg and 1.5 g. These assays are too high and do not meet the marketing authorization indications for the prevention of post-phacocystectomy infections.
  • the private or hospital ophthalmologist unaccustomed to the prescribed pharmaceutical parameters, can not easily easily collect one two-hundred-and-fiftieth of a pre-existing dosage form, let alone dissolve them in a small volume of aqueous solvent without being uncertain about the adequacy of the reconstituted dosage, and this without any Marketing Authorization specific to this indication.
  • hospital pharmacies use freezing. Hospital pharmacists prepare adequate doses and then freeze them.
  • intra-vitreous ophthalmic drugs in particular for the treatment of retinal pathologies. It appears that intra-vitreous injections, which for the moment are carried out without accompanying the active ingredient injected by a preventive antibiotic for intraocular infections, are also likely to generate infections such as those occurring after the interventions on the cataracts, inducing blindness.
  • doctors encounter the same difficulties for all treatment based on unstable injectable active ingredients intravenously, intramuscularly, subcutaneously or in certain organic structures, tissues or cavities delimited, as an example of substances such as peptides or active ingredients derived from biotechnology.
  • This device makes it possible to provide a unique, precise and controlled dosage of active ingredient.
  • it almost instantaneously allows the dissolution of one or more active principle (s), including at very low dose, and the sampling for administration of this or these active principle (s) dissolved , without requiring manipulations or transfers in an external atmosphere from one container to another, likely to cause alterations, losses or human errors.
  • the invention thus makes it possible to ensure instantaneous mixtures in a sterile atmosphere guaranteed, without any externalization of the components used.
  • the invention therefore also relates to the use of the device for these applications.
  • a device 10 comprising a body 12 which can be in any material avoiding evaporation through the wall and able to prevent the action of light or air on the contents.
  • Such a body is advantageously thick monobloc plastic or glass, preferably opacified, pharmaceutical grade, with a high mechanical strength, square, oval, rectangular, triangular or round.
  • This device 10 comprises a head 14, movably secured at least in translation relative to the body 12.
  • This head 14 is able to take a first position P1 of conservation in which said head 14 is distal to the body 12 and a second preparation position P2 in which said head 14 is in a position proximal to the body 12.
  • the body 12 comprises at least one compartment intended to contain a very small volume of at least one pharmaceutical solvent 22, such as physiological saline.
  • a pharmaceutical solvent 22 such as physiological saline.
  • the volume of solvent in a compartment is a volume less than 5 ml, very preferably less than 0.5 ml.
  • the head 14 comprises at least one compartment intended to contain a dose of at least one active ingredient 24 in solid form, for example in the form of lyophilisate, powder, tablet or specific polymeric gel or in liquid form.
  • the active ingredient 24 is in pulverulent or freeze-dried form.
  • the dose of active principle in a compartment is preferably a dose of less than 50 mg, preferably less than 10 mg, or even less than 5 mg.
  • the device according to the invention is suitable for variable dosages according to the type of active principles considered, their specific routes of administration and the number of components and different compartments of the device. It is particularly suitable for administering very low dosages of active ingredients, but can be used for larger dosages.
  • Active ingredient means a substance or combination of substances capable of producing demonstrated pharmacological activity on extra or intracellular tissue or receptor complexes to reduce, prevent or correct an acute or chronic condition or degeneration special.
  • the active ingredient 24 is an antibiotic, even more preferably an antibiotic chosen from the family of beta-lactams, including cephalosporins, in particular cefuroxime or cefazolin.
  • the active ingredient 24 can also be chosen from the active agents treating retinal pathologies, such as retinal angiopathies, retinitis, age-related macular degeneration. These may include principles Intra-vitreous anti-angiogenesis agents such as Pegaptanib sodium, Bevacizumab, Ranibizumab, Anecortane acetate or Squalamine lactate.
  • retinal pathologies such as retinal angiopathies, retinitis, age-related macular degeneration.
  • Intra-vitreous anti-angiogenesis agents such as Pegaptanib sodium, Bevacizumab, Ranibizumab, Anecortane acetate or Squalamine lactate.
  • It may also be a labile active ingredient of peptide nature or derived from biotechnology.
  • the head 14 comprises in its upper part at least one sampling chamber 32 provided with a filter 40 which makes it possible to prevent any particulate contamination of the dissolved active ingredient to be sampled, by ensuring a mechanical filtration of the solution extracted during sampling.
  • the device may comprise several sampling chambers.
  • the sampling chamber 32 must have a suitable size. Its length must be greater than or equal to that of a sampling needle, ie between 8 and 40 mm, so that at the end of the stroke a needle can never damage the filter 40.
  • the filter 40 preferably has a mesh size of between 5 and 75 microns.
  • the body 12 and the head 14 of the device 10 are separated by at least one wall 16 which prevents the active principle 24 from being in contact with the solvent 22 when the head 14 is in the P1 storage position.
  • This wall is preferably a sealed metalloplastic membrane.
  • this wall 16 may be completed by at least one other membrane, intended to prevent any loss of the active ingredient 24 during the manufacture of the device.
  • the device 10 according to the invention also comprises means 18 for breaking the wall 16 so that the active ingredient 24 in solid form comes into contact with the solvent 22 and dissolves therein.
  • the breaking means 18 are means for cutting the wall 16, for example perforating means.
  • the body 12 and the head 14 are equipped with means 26 for translational movement of said head 14 from the distal position to the proximal position, in this case a thread.
  • the container is also provided with safety locking means 28 so as to prevent any involuntary displacement, in translation, of the head 14 relative to the body 12.
  • the means 26 for moving in translation comprise a set of screws 30 carried by the body 12, more particularly by the neck 32 of this body and a thread 34 of the conjugate profile of the thread of the container carried. by the head 14 so as to cooperate by screwing.
  • the locking means 28 comprise a removable ring 36 interposed between the head 14 in a distal position and the body 12.
  • This ring 36 has a C profile which is mounted elastically on the thread 30 carried by the body 12, prohibiting the translational movement of the head 14 relative to the body 12.
  • the head 14 is provided with a piercing protector membrane 38, pierceable.
  • This membrane 38 is intended to be perforated for taking the contents of the device 10 by sterile syringe and needle.
  • this membrane 38 is protected by a protective cap 42 held on the head 14 and a safety tab 44.
  • the device 10 is filled at the body 12 with a pharmaceutical solvent 22 in a sterile environment, then the body 12 is sealed by the laying of the membrane 16, and the head 14 is preferably closed at its bottom. at least one other membrane preventing any loss of the active ingredient 24.
  • the wall 16 is made during the assembly of the body 12 and the solvent 22 that it must contain so as to form a sterile and sealed, sealed single-dose unit.
  • the ring 36 is disposed on the neck around the thread 30, then the head 14 is attached by screwing until it comes into abutment on the ring 36.
  • the dose of active ingredient 24 is deposited in the head 14 which is then sealed in turn by sealing the membrane 38.
  • the protective cap 42 is put in place on the head 14, preventing any perforation of the membrane 38.
  • the safety tab 44 is attached to the head by peripheral bonding.
  • the packaging is not usable and can be preserved, without altering the stable active ingredient in solid form.
  • the user only has to punch this membrane 38 with a mini syringe and a sterile needle to take the contents of the device. It injects through the membrane 38, a volume of air greater than or equal to the volume of drug solution that it wishes to take, in order to create an internal positive pressure during the extraction of the liquid and facilitate the passage of the therapeutic solution to through the filter 40. It retrieves the desired volume of the solution contained in the device 10 by suction in the syringe and deposits this volume at the expected location, for example in the anterior chamber of the eye in the case of the prevention of post-phacocystectomy infections.
  • the sterile needle carried by a suitable syringe allows the immediate administration of the reconstituted solution, whatever the route of administration, intra-ophthalmic, intravenous, intramuscular, subcutaneous, intra-articular, intra-cavitary.
  • the active ingredient is dissolved in the solvent just before its administration, which prevents any premature degradation.
  • a single dose of active ingredient is administered in a precise and controlled manner.
  • the dimensions of the device have been maximized to better reveal the details of constitution but it must be taken into account that it may be a container of 0.5 to 2 ml, extremely small device and difficult to handle.
  • the present invention proposes an improvement to the container which consists of adding a pallet 46 for gripping, advantageously arranged in the lower part of the body 12.
  • This pallet 46 gripping allows a good grip bidigital, despite the small size of the container to allow the user to maneuver the head 14 in rotation.
  • the body may also have in its upper part gripping means 48.
  • the head 14 may comprise on its outer peripheral surface gripping means 50, such as fins.
  • the user is thus ready to maneuver by exerting a torque between the body 12 and the head 14.
  • the pallet 46 has a further handling advantage after rotation of the head relative to the body and after removal of the protective cap 42, that of allowing easy removal of the content using a device adapted.
  • the ring 36 can also be a plastic belt that can be torn or loosened. To facilitate these belt removal operations, a prehensile external pull tab can be added to this belt.
  • the head 14 may comprise at least two compartments 52-1, 52-2, these compartments being separated by at least one wall 54, and possibly by at least one additional membrane preventing any loss of the contents of the compartments during the manufacture of the device .
  • Each compartment 52-1, 52-2 contains at least one active principle and / or an excipient and / or a solvent, at least one compartment of the head 14 containing an active ingredient.
  • the body 12 may also comprise at least two compartments, each compartment being separated by at least one wall and containing at least one active principle and / or excipient and / or solvent, at least one of the compartments of the body 12 comprising a solvent.
  • the device 10 may also comprise intermediate perforating means, 18-1, 18-2, capable of tearing the walls interposed between the compartments, so as to obtain mixtures of substance in a determined order.
  • the body 12 of the device comprises two compartments 52-3, 52-4, separated by at least one wall 16-2.
  • the compartment 52-3 comprises a solvent 22, and the compartment of the head 14 and the compartment 52-4 each comprise at least one active ingredient 24-1 and 24-2.
  • the head 14 and the compartment 52-3 of the body 12 are separated by a wall 16-1.
  • the head 14 and the compartment 52-4 of the body 12 are also provided with means of rupture 18-3 and 18-4 of the walls 16-1 and 16-2 so that the active ingredients 24-1 and 24-2 come into contact with each other. with the solvent 22 and dissolve therein.
  • This embodiment thus makes it possible, in particular, to separate two active principles during their storage, then to dissolve in a preferential order the first and then the second active principle before administration, such as, for example, an anti-angiogenic ophthalmic active ingredient and a preventive antibiotic such as Cefuroxime.
  • the invention can make it possible to bring into contact two solvents each present in contiguous compartments, then to put this liquid mixture in contact with one or more active ingredients, in a given preparation order.
  • the device according to the invention makes it possible to protect the active principle, excipient or other substance in the form of powder, lyoc, tablet, liquid microcapsule, etc., and to carry out mixing and extemporaneous dissolution in a solvent just before 'administration. It is thus possible for certain complex and mutable components to form a device with several separate compartments allowing a successive assembly of these various incompatible substances just before their administration, this in a specific order that is specifically suited to their constitutions and sensitivities physico -chimiques. These compartments can be assembled and arranged according to any industrially feasible embodiment.
  • the device according to the invention can be used for preservation and extemporaneous preparation of an active ingredient or a mixture of unstable active ingredients in solution and / or chemically incompatible for their assembly before intravenous administration. , intramuscular or subcutaneous or injectable in certain organic structures, tissues or cavities delimited.
  • the device according to the invention can be used for the preservation and extemporaneous preparation of antibiotics for intracameral administration to prevent eye infections post-phacocystectomy.
  • the device according to the invention is the preservation and the extemporaneous preparation of ophthalmological active principles for their administration by intra-vitreous injection, in particular in combination with antibiotics for prevention of intraocular infections.
  • the device according to the invention can be used for preservation and extemporaneous repair of anti-angiogenic active ingredients to be administered by intra-vitreous injection.
  • the device can then contain in weak dosages, an antibiotic preventing endophthalmitis, such as cefuroxime, and anti-vitreous anti-angiogenesis active ingredients such as Pegaptanib sodium, Bevacizumab, Ranibizumab, Anecortane acetate or Squalamine Lactate.
  • the device according to the invention can thus advantageously make it possible to associate extemporaneously with intra-vitreous anti-angiogenesis active ingredients with a labile antibiotic with a very low dosage, such as cefuroxime, in order to prevent possible intraocular infections resulting from the injection. of these substances.
  • a labile antibiotic with a very low dosage, such as cefuroxime

Landscapes

  • Health & Medical Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP09745963A 2008-04-17 2009-04-17 Dispositif pour la conservation, la preparation extemporanee et l'administration de principe actif Not-in-force EP2271299B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0852608A FR2930140B1 (fr) 2008-04-17 2008-04-17 Dispositif pour la conservation, la preparation extemporanee et l'administration d'un faible dosage de principe actif
PCT/FR2009/050721 WO2009138644A1 (fr) 2008-04-17 2009-04-17 Dispositif pour la conservation, la preparation extemporanee et l'administration de principe actif

Publications (2)

Publication Number Publication Date
EP2271299A1 EP2271299A1 (fr) 2011-01-12
EP2271299B1 true EP2271299B1 (fr) 2011-10-12

Family

ID=40029345

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09745963A Not-in-force EP2271299B1 (fr) 2008-04-17 2009-04-17 Dispositif pour la conservation, la preparation extemporanee et l'administration de principe actif

Country Status (12)

Country Link
US (1) US8870844B2 (ru)
EP (1) EP2271299B1 (ru)
JP (1) JP5345672B2 (ru)
CN (1) CN102006850B (ru)
AT (1) ATE527976T1 (ru)
BR (1) BRPI0910341A8 (ru)
DK (1) DK2271299T3 (ru)
ES (1) ES2374795T3 (ru)
FR (1) FR2930140B1 (ru)
PT (1) PT2271299E (ru)
RU (1) RU2493811C2 (ru)
WO (1) WO2009138644A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013076129A1 (en) * 2011-11-22 2013-05-30 Novo Nordisk Health Care Ag Barrier element removal

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013004938B8 (pt) 2010-09-02 2020-10-13 Kraft Foods Group Brands Llc recipientes para dispensar concentrados de bebidas
FR2967894B1 (fr) 2010-11-30 2013-11-29 Philippe Perovitch Dispositif de conditionnement, de conservation et de preparation extemporanee d'un ou plusieurs principe(s) actif(s).
WO2012110057A1 (en) * 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
FR2991305B1 (fr) * 2012-06-01 2015-05-01 Assist Publ Hopitaux De Paris Dispositif pour le recueil, le traitement preanalytique, le transport et le broyage d'echantillons solides.
FR3000896B1 (fr) 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
CN105083781A (zh) * 2014-05-09 2015-11-25 广东北航技术转移有限公司 一种具有破坏结构的雾化器
WO2016079265A1 (en) * 2014-11-19 2016-05-26 Ratiopharm Gmbh Oral rehydration composition
FR3031668A1 (fr) 2015-01-20 2016-07-22 Philippe Perovitch Dispositif d'administration d'un principe actif par voie per-muqueuse buccale.
JP6769990B2 (ja) * 2015-04-10 2020-10-14 ドンペ ファーマスーチシ ソシエタ ペル アチオニ 点眼液滴分配装置の製造方法
MA41906A (fr) * 2015-04-10 2018-02-13 Dompe Farm Spa Dispositif de distribution de gouttes oculaires
KR102607495B1 (ko) * 2015-06-16 2023-11-30 베링거잉겔하임베트메디카게엠베하 연결 및 용기 시스템
KR102607491B1 (ko) 2015-06-16 2023-11-30 베링거잉겔하임베트메디카게엠베하 연결 및 용기 시스템
RS64583B1 (sr) * 2015-06-16 2023-10-31 Boehringer Ingelheim Vetmedica Gmbh Spojni i kontejnerski sistem sa nagnutim lomljivim mestom
ITUA20162072A1 (it) 2016-06-30 2017-12-30 Platinum Corp Srl Dropper a volume controllato
FR3053244A1 (fr) 2016-07-01 2018-01-05 Philippe Perovitch Dispositif d'administration d'au moins un principe actif par voie per-muqueuse buccale.
EP3323455B1 (de) 2016-11-21 2021-08-11 Aptar Radolfzell GmbH Inhalationseinrichtung zum zwecke des inhalierens eines tröpfchennebels
DE102018210941A1 (de) * 2018-07-03 2020-01-09 Vetter Pharma-Fertigung GmbH & Co. KG Stopfenvorrichtung, Medikamentenbehälter und Verfahren zur Durchmischung zweier Substanzen in einem Medikamentenbehälter
US20210361568A1 (en) * 2018-08-20 2021-11-25 Hexo Operations Inc. Cannabinoid-containing products, containers, systems, and methods
CN108938188A (zh) * 2018-08-28 2018-12-07 沈阳何氏眼产业集团有限公司 新型滴眼剂瓶
KR102539681B1 (ko) * 2019-05-21 2023-06-08 진영석 내부에 생리 식염수가 수용된 검체 용기
EP3878422A1 (en) * 2020-03-11 2021-09-15 YOS Official B.V. A container for tablets, a combination thereof with a lid and a kit of parts

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2631521A (en) * 1953-03-17 Beverage mixing container
US2275567A (en) * 1933-11-03 1942-03-10 Arthur E Smith Container closure
US2495942A (en) * 1947-06-14 1950-01-31 William A Nosik Multiple chamber container
FR996181A (fr) * 1949-08-13 1951-12-14 Dispositif permettant de mélanger deux produits maintenus normalement séparés dans un même récipient, sans débouchage de celui-ci
US2773591A (en) * 1952-10-22 1956-12-11 Novo Terapeutisk Labor As Vessel with sterile closure for separate storage of at least two substances
US2721552A (en) * 1954-03-29 1955-10-25 Nosik William Andre Multiple chamber container
GB1083335A (en) * 1963-05-28 1967-09-13 Calmic Ltd Storing, mixing and dispensing devices,e.g. for antibiotics
US3441179A (en) * 1967-05-29 1969-04-29 Ways & Means Inc Mixing container
US3467282A (en) * 1968-05-10 1969-09-16 Gilbert Schwartzman Mixing tube
AT318132B (de) * 1969-08-01 1974-09-25 Dentaire Ivoclar Ets Mischbehälter für die Aufnahme von miteinander reagierenden Substanzen für die Herstellung von gebrauchsfertigen pastenförmigen Dentalpräparaten
DE1939315B2 (de) * 1969-08-01 1973-03-15 Etablissement Dentaire Ivoclar, Schaan (Liechtenstein) Mehrkammeriger behaelter fuer die aufnahme von miteinander reagierenden substanzen zur herstellung von gebrauchsfertigen dentalpraeparaten
NL7413077A (nl) * 1974-10-03 1976-04-06 Leer Koninklijke Emballage Houder met schroefdop.
US3924741A (en) * 1975-03-04 1975-12-09 Gibson Ass Inc Two-compartment container
FR2342914A1 (fr) * 1976-03-02 1977-09-30 Oreal Dispositif de conditionnement de deux produits isoles l'un de l'autre avant la distribution
IL52695A (en) * 1977-08-10 1979-11-30 Silmet Ltd Mixing capsule
DE3426739A1 (de) * 1984-07-20 1986-01-30 Robert Finke KG, 5950 Finnentrop Zwei-komponenten-packung
FR2564433B1 (fr) * 1984-05-15 1986-10-03 Oreal Recipient de conditionnement et de distribution d'un produit liquide et d'au moins un produit additionnel separes pendant le stockage
IT1185850B (it) * 1985-08-02 1987-11-18 Zambon Spa Tappo serbatoio contagocce per flaconi
US4865189A (en) * 1988-08-24 1989-09-12 Alcon Laboratories, Inc. Device for storage, mixing, and dispensing of two different fluids
US4903865A (en) * 1988-09-19 1990-02-27 Janowitz C Michael Push button cap containing an additive for containers
US5000314A (en) * 1989-01-23 1991-03-19 Bristol-Myers Company Unit dose package
US5217433A (en) * 1991-05-24 1993-06-08 Merck & Co., Inc. Medication container for mixing two components
US5330426A (en) * 1992-08-13 1994-07-19 Science Incorporated Mixing and delivery syringe assembly
IT227015Y1 (it) * 1992-11-27 1997-09-09 Ibsa Inst Biochimique Sa Dispositivo dosatore per sciroppi estemporanei multidose ad uso farmaceutico
US5772017A (en) * 1996-10-25 1998-06-30 Kang; Heung Sun Beverage mixing dispenser device
IT1292677B1 (it) * 1997-02-28 1999-02-11 Bormioli Metalplast Spa Confezione per mantenere separati dei prodotti prima dell'uso.
AU728008C (en) * 1997-03-12 2004-09-16 Fredrick Michael Coory Cap for a container
MX203911B (es) * 1997-05-21 2001-08-24 Pablo Andres Robles Gonzalez Aparato contenedor de substancias solubles en medios fluidos y metodo para la preparacion de mezclas en sitio.
FR2765861B1 (fr) * 1997-07-08 1999-09-24 Oreal Dispositif pour le conditionnement separe de deux composants et procede de fabrication
US6513650B2 (en) * 1997-10-14 2003-02-04 Biogaia Ab Two-compartment container
US6098795A (en) * 1997-10-14 2000-08-08 Mollstam; Bo Device for adding a component to a package
US5941380A (en) * 1998-01-10 1999-08-24 Rothman; David Device for dispensing flowable material
US5927549A (en) * 1998-03-20 1999-07-27 Aptargroup, Inc. Dispensing structure with frangible membrane for separating two products
DE19812657A1 (de) * 1998-03-23 1998-12-24 Wella Ag Zweikomponentenbehälter
US6378714B1 (en) * 1998-04-20 2002-04-30 Becton Dickinson And Company Transferset for vials and other medical containers
US5950819A (en) * 1998-05-08 1999-09-14 Sellars; Andy Storage, admixing, and dispensing system
US6003728A (en) * 1998-10-22 1999-12-21 Aptargroup, Inc. Dispensing structure with an openable member for separating two products
FR2789372B1 (fr) * 1999-02-10 2001-04-13 Oreal Dispositif pour le stockage de trois composants, leur melange et la distribution du melange ainsi obtenu
JP2003514722A (ja) * 1999-11-17 2003-04-22 マイケル クーリ フレドリック 容器用貫穿キャップ
AU6066799A (en) * 1999-11-26 2001-05-31 Lily Hsu Container device for separately enclosing two different substances
GB2366288B (en) * 2000-08-31 2004-03-10 Inge Spa Sealing device for a container of substances to be kept separate up to their dispensing
US6533113B2 (en) * 2000-12-01 2003-03-18 Brett Moscovitz System, devices and methods for storing and mixing substances
US6527110B2 (en) * 2000-12-01 2003-03-04 Brett Moscovitz Device for storing and dispensing a substance by mating with a container and associated methods
US6387073B1 (en) * 2000-12-06 2002-05-14 Weiler Engineering, Inc. Hermetically sealed container with medicament storing and dispensing insert
US20020157970A1 (en) * 2001-04-26 2002-10-31 Carlson Stephen G. Beverage flavor dispensing cap
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
JP2004041379A (ja) * 2002-07-10 2004-02-12 Shionogi & Co Ltd 輸液容器及び薬剤収容器
US6854595B2 (en) * 2002-07-15 2005-02-15 Danny Kiser Container closure containing a mix
JP2004075133A (ja) * 2002-08-20 2004-03-11 Nippon Tansan Gas Co Ltd 容器の封止機構及びその機構に使用するキャップ
US6705490B1 (en) * 2002-09-12 2004-03-16 Eric K. Lizerbram Self contained additive reservoirs for use with beverage containers
US7210575B2 (en) * 2002-09-26 2007-05-01 Boehringer Ingelheim International Gmbh Two-component packaging unit
US7942861B2 (en) * 2002-10-22 2011-05-17 Baxter International Inc. Fluid container with access port and safety cap
US6974024B2 (en) * 2003-04-12 2005-12-13 Young Kook Cho Cap device for mixing different kinds of materials separately contained therein and in bottle
US6994211B2 (en) * 2003-04-12 2006-02-07 Young Kook Cho Cap device for mixing different kinds of materials separately contained therein and in bottle
US6926138B1 (en) * 2003-08-18 2005-08-09 Mark Floyd Basham Bottle cap including an additive dispenser
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US20050115845A1 (en) * 2003-11-28 2005-06-02 Cho Young K. Cap device for mixing different kinds of materials separately contained therein and in bottle
ITMI20032619A1 (it) * 2003-12-30 2005-06-30 Liteco S R L Tappo dosatore per polveri o liquidi
US20050173271A1 (en) * 2004-02-05 2005-08-11 Henri Levi Instant drink bottle
RU2007120575A (ru) * 2004-11-04 2008-12-10 Виз Энтерпрайсиз Многокамерная емкость и колпачок для нее
US7506782B2 (en) * 2004-12-24 2009-03-24 Ronald J Walters Single use unit dosage dispensing closure
US7249690B2 (en) * 2004-12-24 2007-07-31 Erie County Plastics Corporation Independent off-bottle dispensing closure
US20060006077A1 (en) * 2004-12-24 2006-01-12 Erie County Plastics Corporation Dispensing closure with integral piercing unit
JP4808415B2 (ja) * 2005-02-01 2011-11-02 大成化工株式会社 ２成分混合容器
US7308915B2 (en) * 2005-04-21 2007-12-18 Jpro Dairy International, Inc. Packaging system for storing and mixing separate ingredient components
JP2007282891A (ja) * 2006-04-18 2007-11-01 Shinko Chemical Co Ltd バイアル用のキャップ

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013076129A1 (en) * 2011-11-22 2013-05-30 Novo Nordisk Health Care Ag Barrier element removal

Also Published As

Publication number Publication date
RU2493811C2 (ru) 2013-09-27
JP5345672B2 (ja) 2013-11-20
US8870844B2 (en) 2014-10-28
ATE527976T1 (de) 2011-10-15
CN102006850A (zh) 2011-04-06
PT2271299E (pt) 2012-01-11
ES2374795T3 (es) 2012-02-22
DK2271299T3 (da) 2012-01-23
WO2009138644A1 (fr) 2009-11-19
BRPI0910341A8 (pt) 2019-01-29
BRPI0910341A2 (pt) 2016-04-12
EP2271299A1 (fr) 2011-01-12
WO2009138644A9 (fr) 2010-01-07
JP2011519587A (ja) 2011-07-14
CN102006850B (zh) 2014-12-03
RU2010146669A (ru) 2012-05-27
FR2930140B1 (fr) 2011-04-22
US20110054437A1 (en) 2011-03-03
FR2930140A1 (fr) 2009-10-23

Similar Documents

Publication Publication Date Title
EP2271299B1 (fr) Dispositif pour la conservation, la preparation extemporanee et l'administration de principe actif
RU2471474C2 (ru) Устройство для расфасовки и сублингвального введения активных начал
EP0625917B1 (fr) Dispositif pour la preparation d'une solution, d'une suspension ou d'une emulsion d'une substance medicinale
EP1223999B1 (fr) Dispositif pour reconstituer une solution, une suspension ou une dispersion therapeutique
KR20170056605A (ko) 용액 전달 장치 및 방법
WO1990007318A1 (fr) Flacon de stockage et de transfert conçu pour stocker un composant d'une substance medicamenteuse
WO1995032015A1 (fr) Dispositif pour la preparation d'une solution, d'une suspension ou d'une emulsion d'une substance medicinale
US9918901B2 (en) Device for packaging, storing, and extemporaneously preparing a plurality of active principles
FR3031668A1 (fr) Dispositif d'administration d'un principe actif par voie per-muqueuse buccale.
WO2018002535A1 (fr) Dispositif d'administration d'au moins un principe actif par voie per-muqueuse buccale
LU88699A1 (fr) Seringue pharmaceutique à double chambres pour la conservation séparée de deux produits différents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009003093

Country of ref document: DE

Effective date: 20111215

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20111226

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20111012

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2374795

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120222

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20111012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120112

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120113

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120112

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

26N No opposition filed

Effective date: 20120713

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009003093

Country of ref document: DE

Effective date: 20120713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090417

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602009003093

Country of ref document: DE

Representative=s name: STAUDT IP LAW, DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20160323

Year of fee payment: 8

Ref country code: LU

Payment date: 20160425

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20160405

Year of fee payment: 8

Ref country code: MC

Payment date: 20160418

Year of fee payment: 8

Ref country code: IE

Payment date: 20160420

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20160415

Year of fee payment: 8

Ref country code: DK

Payment date: 20160421

Year of fee payment: 8

Ref country code: AT

Payment date: 20160422

Year of fee payment: 8

Ref country code: BE

Payment date: 20160421

Year of fee payment: 8

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20170412

Year of fee payment: 9

Ref country code: GB

Payment date: 20170420

Year of fee payment: 9

Ref country code: FR

Payment date: 20170426

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20170508

Year of fee payment: 9

Ref country code: IT

Payment date: 20170412

Year of fee payment: 9

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20170430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 527976

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170417

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170417

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170502

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171017

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170417

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170430

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170418

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170417

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170430

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602009003093

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180417

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180430

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20190912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180418